Fusion protein binding to CD47 protein and application thereof
AssigneesHangzhou Sumgen Biotech Co., Ltd., Sumgen Mab (Beijing) Biotech Co., Ltd.
InventorsMing Lv, Xiaoran Ding, Shiwei Miao, Bin Tan, Xuegong Wang
Life of this patent
Estimating the term…
Abstract
Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10−8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRPα without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.
Claims9
A human SIRPα (signal regulatory protein α) domain mutant, wherein the human SIRPα domain mutant comprises an amino acid sequence as set forth in any one of SEQ ID NOs:
- 2, 3, 10, 11, 12 and 14.
Dependencies are inferred from the claim text.